Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07665723 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07665723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07665723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Recruiting
Start date
June 29, 2026
Completion date
December 31, 2030
Enrollment
25 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

active ulcerative colitis